Oseltamivir
As of the edition of 20 October 2026, Oseltamivir is a small molecule: marketed, first approved in 1999 (CH).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2002
- Kind
- Small molecule
- Brand name
- Tamiflu
- First approved
- 21 September 1999 (CH)
- Approvals on record
- 14 in 5 regions
- Holder of the most recent approval
- Roche; 4 holders in all
- Registered trials
- 93, 18 stopped early
- Disease areas
- Infections; Lungs and airways; Blood and lymph; Animal diseases; Cancer; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 10 | 5 | 2 | 0 |
| Phase 1 | 31 | 26 | 0 | 3 |
| Phase 2 | 22 | 12 | 2 | 7 |
| Phase 3 | 12 | 6 | 1 | 3 |
| Phase 4 | 18 | 10 | 0 | 5 |
| All trials | 93 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Roche | Applicant, Later holder and Lead sponsor of trials | 1999 to now |